Journal article
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors
Monica Tang, Rachel L O'Connell, Frederic Amant, Philip Beale, Orla McNally, Katrin M Sjoquist, Peter Grant, Alison Davis, Peter Sykes, Linda Mileshkin, Tania Moujaber, Catherine J Kennedy, Anna deFazio, King Tan, Yoland Antill, Jeffrey Goh, Tony Bonaventura, James Scurry, Michael Friedlander
Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2019
Abstract
OBJECTIVE: Treatment options are limited for patients with recurrent/metastatic low-grade ovarian cancers (LGOCs) and serous borderline ovarian tumors (SBOTs) as response rates to chemotherapy are low. A subset of patients appears to derive clinical benefit from antiestrogens, but most studies have been retrospective and clinical benefit rates (CBR) remain uncertain. The primary aim of PARAGON was to prospectively investigate the CBR of anastrozole, an aromatase inhibitor, in patients with estrogen receptor (ER) and/or progesterone receptor (PR) positive LGOC and SBOT. METHODS: Post-menopausal women with ER-positive and/or PR-positive recurrent/metastatic LGOCs and SBOTs and evaluable diseas..
View full abstractRelated Projects (1)
Grants
Awarded by Cancer Australia
Awarded by Cancer Australia Priority-driven Collaborative Cancer Research Scheme Project
Awarded by Cancer Council New South Wales
Awarded by National Health and Medical Research Council
Awarded by Cancer Institute NSW
Funding Acknowledgements
This research was supported by Cancer Australia Grant 632740 (2009-2011), Cancer Australia PdCCRS 1063014 (2014-2016), Cancer Australia Priority-driven Collaborative Cancer Research Scheme Project Grant APP1142697, Cancer Council New South Wales (RG-15-23). The Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group, was funded by the National Health and Medical Research Council Enabling Grants ID 310670 & ID 628903 and the Cancer Institute NSW Grants ID 12/RIG/1-17 & 15/RIG/1-16. FA is senior researcher for the Flemish Research Fund (F.W.O.). LM was supported by a Victorian Cancer Agency Clinical Research Fellowship.